These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17915079)

  • 21. [Life-threatening heart failure caused by ADHD medication. Five case reports described].
    Wikström G; Kvidal P; Hagström E
    Lakartidningen; 2012 Nov 7-13; 109(45):2016-8. PubMed ID: 23240309
    [No Abstract]   [Full Text] [Related]  

  • 22. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006.
    van den Ban E; Souverein P; Swaab H; van Engeland H; Heerdink R; Egberts T
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):55-61. PubMed ID: 20166797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder.
    Hazell P
    Australas Psychiatry; 2004 Dec; 12(4):369-75. PubMed ID: 15715810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of adult ADHD and comorbid disorders.
    Young JL
    CNS Spectr; 2006 Oct; 11(10 Suppl 11):10-2. PubMed ID: 17712918
    [No Abstract]   [Full Text] [Related]  

  • 28. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders.
    Reichow B; Volkmar FR; Bloch MH
    J Autism Dev Disord; 2013 Oct; 43(10):2435-41. PubMed ID: 23468071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The practice and problem of therapeutic agents for AD/HD].
    Tanaka H; Miyajima T
    No To Hattatsu; 2010 May; 42(3):213-6. PubMed ID: 23858580
    [No Abstract]   [Full Text] [Related]  

  • 31. Azstarys (serdexmethylphenidate/dexmethylphenidate) for ADHD.
    Med Lett Drugs Ther; 2021 Oct; 63(1634):157-159. PubMed ID: 34550957
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder.
    Garg J; Arun P; Chavan BS
    Indian Pediatr; 2014 Jul; 51(7):550-4. PubMed ID: 25031133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies.
    Fredriksen M; Halmøy A; Faraone SV; Haavik J
    Eur Neuropsychopharmacol; 2013 Jun; 23(6):508-27. PubMed ID: 22917983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.
    Fuentes J; Danckaerts M; Cardo E; Puvanendran K; Berquin P; De Bruyckere K; Montoya A; Quail D; Escobar R
    J Clin Psychopharmacol; 2013 Dec; 33(6):766-74. PubMed ID: 23963057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.
    Cortese S; Holtmann M; Banaschewski T; Buitelaar J; Coghill D; Danckaerts M; Dittmann RW; Graham J; Taylor E; Sergeant J;
    J Child Psychol Psychiatry; 2013 Mar; 54(3):227-46. PubMed ID: 23294014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD.
    Robb AS; Findling RL; Childress AC; Berry SA; Belden HW; Wigal SB
    J Atten Disord; 2017 Dec; 21(14):1180-1191. PubMed ID: 24874348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades.
    Ibrahim K; Donyai P
    J Atten Disord; 2015 Jul; 19(7):551-68. PubMed ID: 25253684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline.
    Banaschewski T; Coghill D; Santosh P; Zuddas A; Asherson P; Buitelaar J; Danckaerts M; Döpfner M; Faraone SV; Rothenberger A; Sergeant J; Steinhausen HC; Sonuga-Barke EJ; Taylor E
    Eur Child Adolesc Psychiatry; 2006 Dec; 15(8):476-95. PubMed ID: 16680409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atomoxetine-associated hemospermia: a case report.
    Raj YP
    J Clin Psychiatry; 2008 Jul; 69(7):1189. PubMed ID: 18687023
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.